Hebei Medical University Fourth Hospital

• Trastuzumab/Pertuzumab With Fulvestrant and Kurmoxilil in HR+/HER2+ Early Breast Cancer

  Phase 2, Not yet recruiting, 31 people, 5 Oct 2026

• NCT07782840

  Phase 2, Not yet recruiting, 40 people, 24 Aug 2026

• NCT07635342

  Phase 2, Recruiting, 182 people, 9 Jun 2026

• NCT07586826

  Collaborator, Phase 2, Recruiting, 220 people, 14 May 2026

• NCT07586813

  Collaborator, Phase 2, Recruiting, 220 people, 14 May 2026

• NCT07492394

  Phase 2, Recruiting, 60 people, 25 Mar 2026

• NCT07383285

  Collaborator, Phase 2, Not yet recruiting, 106 people, 3 Feb 2026

• NCT07307443

  Collaborator, Phase 2, Not yet recruiting, 28 people, 29 Dec 2025

• NCT07200947

  Collaborator, Phase 2, Not yet recruiting, 28 people, 1 Oct 2025

• NCT07083375

  Collaborator, Phase 2, Not yet recruiting, 56 people, 24 Jul 2025

• Efficacy and Safety of Serplulimab Combined With Chemotherapy as Neoadjuvant Treatment for Locally Advanced Gastric Cancer or Adenocarcinoma of Esophagogastric Junction

  Collaborator, Phase 2, Active, not recruiting, 116 people, 29 Aug 2024

• NCT06390982

  Collaborator, Phase 2, Not yet recruiting, 46 people, 30 Apr 2024

• NCT06086457

  Collaborator, Phase 3, Recruiting, 436 people, 17 Oct 2023

• NCT06084897

  Collaborator, Phase 2, Recruiting, 120 people, 16 Oct 2023

• NCT05512780

  Phase 2, Status unknown, 30 people, 23 Aug 2022

• NCT05244798

  Collaborator, Phase 3, Not yet recruiting, 420 people, 17 Feb 2022

• NCT05086627

  Phase 2, Completed, 118 people, 21 Oct 2021

• NCT05004142

  Collaborator, Phase 2, Status unknown, 70 people, 13 Aug 2021

• NCT04841720

  Collaborator, Phase 1, Status unknown, 22 people, 12 Apr 2021

• NCT04807673

  Collaborator, Phase 3, Recruiting, 342 people, 19 Mar 2021

Sources: clinicaltrials.gov